Medication for Prenatal Depression: Safety, Options, and What to Ask

The question of medication for depression during pregnancy is one of the most anxiety-producing decisions a pregnant person can face — and also one of the most consequential ones to get right. The stakes feel high in both directions: the risk of medication affecting the baby, and the risk of untreated depression affecting both the parent and the pregnancy.

Navigating this decision requires accurate information, not fear. Here is what the evidence actually shows.

The Framework: Weighing Risks on Both Sides

The decision about medication during pregnancy is not "medication vs. no risk." It is "risks of treatment vs. risks of no treatment." Untreated moderate-to-severe depression during pregnancy carries real risks:

• Reduced prenatal care engagement and self-care (nutrition, rest, prenatal visits)
• Elevated cortisol and stress hormones, which cross the placenta
• Some associations in the research with adverse pregnancy outcomes (though causality is difficult to establish)
• Dramatically elevated risk for postpartum depression
• Impacts on maternal-infant attachment in the early months

These risks must be part of the calculation — not just the risks of medication.

SSRIs: The Most Commonly Used Antidepressants During Pregnancy

Selective serotonin reuptake inhibitors (SSRIs) are the most extensively studied antidepressants in pregnancy. Decades of research have produced a reasonably clear picture of their safety profile.

Sertraline (Zoloft) is generally considered the preferred SSRI during pregnancy based on the volume of safety data available. It has been used by tens of thousands of pregnant people in studied populations. Studies have not found consistent evidence of increased risk for major malformations.

Fluoxetine (Prozac) also has a substantial safety record in pregnancy. It has a longer half-life than sertraline, which means it stays in the system longer but also that doses are more forgiving.

Escitalopram (Lexapro) has favorable tolerability and is commonly used, with a growing safety evidence base.

Paroxetine (Paxil) is generally avoided during the first trimester due to early studies suggesting possible cardiac considerations, though subsequent research has been mixed. Your provider may counsel against it particularly early in pregnancy.

What the Research Actually Shows

The evidence on SSRIs in pregnancy includes:

• No consistent evidence of major structural malformations with commonly used SSRIs at therapeutic doses
• Neonatal Adaptation Syndrome (NAS): Babies born to mothers on SSRIs may experience temporary symptoms (tremor, irritability, feeding difficulties) in the first days of life. These are typically mild and resolve without medical intervention. They are not a reason to stop medication abruptly in the third trimester.
• Persistent Pulmonary Hypertension of the Newborn (PPHN): Early studies raised concern; subsequent larger studies have not consistently confirmed elevated risk at clinical levels. This remains an area of monitoring.
• Neonatal neurobehavioral effects: Some studies find temporary neurobehavioral differences in exposed neonates; most resolve in the first weeks.

The American College of Obstetricians and Gynecologists (ACOG) and the American Psychiatric Association (APA) have both published guidance supporting the use of SSRIs during pregnancy when benefits outweigh risks — which, for moderate-to-severe depression, they typically do.

Having the Conversation with Your Provider

You deserve a thorough, evidence-based conversation — not a rushed prescription or a dismissal of your concerns. Questions to bring:

• What is the evidence for this specific medication during pregnancy?
• What symptoms are you treating and what does "adequate response" look like?
• What is the plan if side effects are significant?
• What is the plan for the neonatal period and the postpartum transition?
• What is the tapering plan if I decide to stop?

Important: Do Not Stop Abruptly

If you are currently taking an antidepressant and become pregnant, do not stop the medication without talking to your provider first. Abrupt discontinuation can cause a severe depressive relapse and withdrawal symptoms that are more harmful than continued, monitored use. Tapering, if appropriate, is done slowly and under medical supervision.

Therapy First, or Alongside

For mild to moderate prenatal depression, therapy (CBT, IPT) is recommended as a first-line option before or alongside medication. For moderate to severe depression, medication combined with therapy typically produces better and faster outcomes than either alone. The goal is not to avoid medication at all costs — it is to choose the safest, most effective treatment for your specific situation.

Your mental health during pregnancy matters. You are allowed to treat it.